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The antinociceptive effect of morphine and oxycodone is mediated preferentially at m and k receptors, respectively. The aim of this
study was to evaluate the analgesic profile of the combination of morphine and oxycodone in cancer pain, compared to the standard
administration of morphine alone. Controlled-release formulations of oxycodone (CRO) and morphine (CRM) were compared in 26
patients. The study started with an open-label, randomised titration phase to achieve stable pain control for 7 days, followed by a
double-blind, randomised crossover phase in two periods, 14 days each. At any point, patients were allowed to use oral immediate-
release morphine (IRM) as needed, in order to keep visual analogue scale p4. Pain, satisfaction, adverse effects and number of daily
rescue morphine tablets were assessed. A total of 22 patients were evaluated. The weekly upload consumption ratio in morphine/
oxycodone was 1:1.8 (1.80, 1.83, 1.76, 1.84). The weekly IRM consumption was higher in patients having CRM compared to patients
having CRO (ratio morphine/oxycodone: 1.6, 1.6, 1.6, 1.7) (Po0.05). Patients receiving oxycodone complained of less nausea and
vomiting. The rescue morphine analgesic consumption was 38% higher in patients receiving only morphine, compared to patients
receiving both morphine and oxycodone. The results suggest that the combination of morphine/oxycodone (opioids with differential
preferential sites of action) can be a useful alternative to morphine alone, resulting in a better analgesia profile and less emesis.
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Controlled-release morphine (CRM) or controlled-release oxyco-
done (CRO) are among the pharmacological alternatives in the
management of chronic cancer pain. Although both drugs have
been used regularly, each drug has been individually evaluated,
and as a final result, each patient has normally used either
morphine or oxycodone alone (Heiskanen and Kalso, 1997; Mucci-
LoRusso et al, 1998; Heiskanen et al, 2000; Klepstad et al, 2003).
Among the strategies for the treatment of cancer pain, there is
interest in the coadministration of opioids that act on different
receptors (Heiskanen et al, 2000; Ripamonti and Dickerson, 2001).
For instance, the antinociceptive effect of morphine and the
semisynthetic opioid oxycodone appears to be mediated prefer-
entially at m and k receptors, respectively (Ross and Smith, 1997;
Nielsen et al, 2000), and oxycodone may offer enhanced analgesia
when combined with morphine.
The aim of this study was to evaluate the analgesic profile of the
combination of the opioid morphine and oxycodone in chronic
cancer pain, compared to the standard administration of morphine
alone. Immediate-release morphine (IRM) was used as an escape
analgesic in order to obtain the information related to the
interaction morphine/oxycodone.
MATERIALS AND METHODS
The Ethical Committee of the University of Sa ˜o Paulo’s Teaching
Hospital, Ribeira ˜o Preto, approved the study protocol. Controlled-
release formulations of oxycodone and CRM were evaluated in 26
patients with chronic cancer pain of the visceral and somatic type
(either oropharynx, lung, colon, gastric, ovary or prostate gland, as
described in Table 1), after informed consent of the patients. The
concept of visual analogue scale (VAS), which consisted of a 10cm
line with 0 equalling ‘no pain at all’ or ‘no nausea’, and 10 equalling
‘the worst possible pain’ or ‘worst possible nausea’ was introduced
previously. Before enrolling in this actual study, patients received
3–4mgkg
 1 tramadol, plus nonsteroidal anti-inflammatory drugs;
however, they still complained of pain VAS X4cm. As part of the
protocol, all patients were taking oral 25mg amitriptyline at
bedtime.
The study was started with an open-label, randomised titration
phase to achieve stable pain control for 7 days. At this initial phase,
patients used only IRM and had free access to it in order to keep
pain VAS o4cm. After stable pain relief was achieved, this was
followed by a double-blind, crossover phase in two periods, 14
days each. Each patient acts as his/her own control to minimise the
interindividual variability of response in this group of patients,
and no period of washout was allowed for ethical reasons. At this
phase, patients did not know which treatment they were enrolled
in. The optimum opioid dosage was calculated on a daily basis, and
the consumption ratio of oxycodone to morphine was set at 1:1.8,
as part of the study protocol. In the literature, this ratio has varied
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lfrom 1:1; 1:2; 2:3; 3:4 (Heiskanen and Kalso, 1997; Zhukovsky
et al, 1999; Hanks et al, 2001). Immediate-release morphine was
used as an escape analgesic during the second phase (double blind)
of the study in order to get the information related to the
morphine/oxycodone interaction.
Patients were randomised to receive either CRO (14 days)
followed by CRM (14 days) (n¼13), or the same drugs in inverse
order (n¼13), and were followed on a weekly basis. The doses of
either CRM or CRO were assigned daily by the pharmaceutical,
who was aware of the drugs and treatment, and set at 1:1.8 by the
same pharmaceutical (one of the authors). The tablets of IRM were
substituted by the respective controlled-release formulation,
always by this same investigator. The anaesthesiologists who
collected the data weekly were blind to the treatments during the
crossover phase. At any point, patients were allowed to use oral
IRM (10mg tablets) as an escape analgesic, as needed, in order to
keep the numeric value of the pain VAS p4cm. Patients were
asked to assess pain intensity, patient satisfaction, adverse effects
and number of rescue morphine tablets, and a different
investigator unaware of the treatments, recorded the data weekly.
All patients were cooperative and understood the protocol.
The final collected data were evaluated for each period (14 days)
for each patient, related to the consumption of IRM, and to the
final ratio of the weekly CRO/CRM, in order to check the initial
assumption of the relation of morphine/oxycodone to be 1:1.8,
made always by the pharmaceutical not involved in data collection.
At the end of the study, every patient had received (1) CRM and
IRM (the morphine-alone phase), and (2) CRO and IRM (the
combined phase). The phase entitled ‘morphine alone’ received
only morphine as analgesic during the 14-day period. The phase
entitled ‘combined’ received both oxycodone and morphine during
the 14-day period. The IRM consumption was indicative of the
analgesic interaction between morphine and oxycodone.
Statistical analysis
The statistical analysis for the opioid consumption was performed
using the Mann–Whitney U-test and the Wilcoxon signed-rank
test. Adverse effects were compared using the w
2 test. Significance
was set at Po0.05.
RESULTS
Of the 26 patients enrolled in the study, 22 were evaluated.
Withdrawals were due to death unrelated to the study (one
patient), uncontrollable nausea and vomiting (one patient), and
unstable pain control requiring spinal drugs (two patients). The
population was 59719 years old, 5278kg of weight, 16377cmof
height and the male:female ratio was 15:7. The number of
patients receiving concomitant radiation therapy or chemotherapy
during the study, and the origin of cancer are described in Tables 1
and 2. Although eight patients complained of emesis while taking
only morphine (CRM and IRM), three of them refereed
dissatisfaction and would prefer oxycodone because of the high
frequency of vomiting, which was not related to chemotherapy.
The total of five patients enrolled in radiation therapy had it
regularly throught the study protocol.
The weekly opioid consumption ratio of morphine/oxycodone
was set on a weekly basis at 1:1.8 in all phases (mean 1.80, 1.83,
1.76, 1.84) by the pharmaceutical. The mean final weekly dose of
morphine and oxycodone (mg) is described in Figure 1. When the
results of the two phases were compared, the patients consumed
38% more IRM when using CRM and IRM, compared to the
‘combined phase’ (i.e. when patients received both CRO and IRM).
The range of morphine daily consumption (mg) for the morphine-
alone phase was: first week 20–60mg; second week 30–90mg;
third week 40–90mg; and fourth week 60–90mg. The range of
oxycodone daily consumption (mg) for the combined phase was:
first week 20–40mg; second week 20–40mg; third week 20–
60mg; and fourth week 20–60mg.
The mean daily IRM consumption was higher in patients having
CRM compared to patients having CRO, independent of which
opioid drug was administered first (morphine/oxycodone ratio 1.6,
1.6, 1.6, 1.7) (Figure 2) (Po0.05). The daily pain VAS was less than
4cm in all patients, as part of the study design, and not different
among the phases (P40.05).
Related to side effects, patients receiving oxycodone complained
of less nausea and vomiting, compared to patients receiving
morphine only (Po0.05). The incidence of dry mouth, somno-
lence, hallucination, constipation, pruritus, sensation of empty
head, anorexia, dyspnoea and good acceptance to the study drugs
was not different among patients, independent of the phases
(Table 3; P40.05). There were no reports of hallucinations or
dyspnoea in either group.
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Figure 1 Mean final weekly doses of CRM and CRO (mg) are described
in bars. The lines over the bars indicate the standard deviation of the mean.
The consumption ratio of CRM/CRO was 1.80, 1.83, 1.76 and 1.84, during
the study period, set by the pharmaceutical.
Table 1 Origin of cancer in the population studied
Origin of cancer Number of patients
Oropharynx 9
Lung 3
Colon 4
Gastric 2
Ovary 2
Prostate gland 2
Total no. of patients 22
Table 2 Number of patients having adjuvant therapies
Adjuvant therapies Number of patients
Radiation 1
Chemotherapy 6
Radiation/chemotherapy 4
None 11
Total no. of patients 22
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The results of the study have demonstrated that patients suffering
from cancer pain receiving the combination of morphine and
oxycodone consumed significantly less escape doses of IRM, which
was 38% higher in patients receiving morphine only. The data
suggest that the combination of morphine/oxycodone (Ross and
Smith, 1997; Nielsen et al, 2000) can be a useful alternative to
morphine alone, resulting in a better analgesia profile, which is in
accordance with animal studies. Coadministration of subantino-
ciceptive doses of oxycodone with morphine to rats by both
intracerebroventricular and systemic routes (intraperitoneal and
subcutaneous) resulted in synergistic levels of antinociception
(Ross et al, 2000). Behaviourally, rats coadministered subantino-
ciceptive doses of oxycodone and morphine were not different
from control rats related to sedation, while showing antinocicep-
tion (Ross et al, 2000).
In accordance with the World Health Organisation guidelines
for cancer pain relief, when initiating treatment, controlled-release
preparations of opioids are generally favoured, and are combined
with IRM to prevent or treat breakthrough pain (Enting et al,
2001). In the present study, the optimum opioid dosage was
calculated on a daily basis, and the consumption ratio of
oxycodone to morphine was set at 1:1.8, as part of the study
protocol. In the literature, this ratio has varied from 1:1, 1:2, 2:3,
3:4 (Heiskanen and Kalso, 1997; Zhukovsky et al, 1999; Hanks
et al, 2001). Washout periods cannot be used for ethical reasons,
and a better design including immediate-release oxycodone could
not have been carried out due to its unavailability in Brazil.
However, the absence of a washout period was overcome by the
fact that half of the patients had started the medication with
oxycodone, and the other half had started with morphine.
Adjuvant therapies that could affect pain control, such as radiation
and chemotherapy, were carried out throught the protocol by the
patients involved, as detailed in Table 1, and should not interfere
with the final results, as every patient worked as his/her own
control.
As part of the protocol, all patients were exposed to IRM prior to
randomisation to CRM or CRO, potentially producing tolerance.
Opioids that interact with m- and/or k-binding sites demonstrate
an adaptation process described as desensitisation, due to a
reduced interaction with the internal second-messenger system of
G-protein (Freye and Latasch, 2003). Repeated stimulation of k-
opioid receptors leads to the heterologous upregulation of m-
opioid receptor functions in the thalamus and periaqueductal grey
regions, which may be associated with the supersensitivity of m-
opioid receptor-mediated antinociception (Narita et al, 2003), and
k-receptors may be involved in multiple mechanisms in the
mesencephalon (Sun and Dalman, 2003). As a consequence, the
possibility of tolerance development during the first open phase
would rather interfere with patients taking oxycodone, an opioid
with a preferential site of action at k receptors. In spite of this, the
final data revealed that it probably did not occur at the time the
study was conducted, based on the lesser IMR consumption in the
combined phase.
Despite the preferential action at k receptors (Ross and Smith,
1997; Nielsen et al, 2000), oxycodone is an opioid analgesic that
closely resembles morphine. Oxymorphine, the active metabolite
of oxycodone, is formed in a reaction catalysed by the cytochrome
isoenyme CYP2D6, which is under polymorphic, genetic control
and severely impaired by liver dysfunction. However, the role of
oxymorphone in the analgesic effect of oxycodone is not yet clear
(Heiskanen et al, 2000). Although gender differences exist in
response to oxycodone either due to pharmacodynamics or
differences in metabolism related to reduced CYP2D6 in females
(Davis et al, 2003), in the present study, each patient participated
of both study groups, and acts as his/her own control, minimising
any analgesic tendency in the female population. In addition, an
unidentified metabolite other than oxymorphone appears to be a
potent m agonist (Poyhia et al, 1993), and the intrinsic efficacy of
oxycodone that may not correlate with binding affinity is not
known (Duttaroy and Yoburn, 1995).
Unlike oxycodone, the active metabolite of morphine, mor-
phine-6-glucorinide, appears to have a better toxicity profile and a
similar analgesic effect compared to morphine (Cann et al, 2002).
While patients received CRM, the consumption of IRM was 38%
higher compared to the combination group, suggesting a better
profile of the association of opioids with preferentially binding
sites at m and k receptors (Nielsen et al, 2000), such as morphine
and oxycodone.
Nevertheless, pain relief and side effects such as emesis,
sedation, itching and hallucinations have been described following
morphine administration, while being less frequent at equianalge-
sic doses after oxycodone (Heiskanen and Kalso, 1997; Mucci-
LoRusso et al, 1998). In the actual study, when patients received
the combination of oxycodone and morphine, they complained of
less nausea and vomiting, in accordance with others (Heiskanen
and Kalso, 1997), while constipation has been reported to be more
frequent after oxycodone alone (Heiskanen and Kalso, 1997). Side
effects such as dry mouth, somnolence, constipation, pruritus,
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Figure 2 Mean daily number of rescue analgesic IRM (10mg) at the end
of each week. The weekly IRM consumption was higher in patients having
CRM compared to patients having CRO (Po0.05). Morphine values: 2(0–
2.5); 2(0–3); 2(0–2); 2(1–3). Oxycodone values: 1(0–3); 0.5(0–2); 1(0–
2); 1(0–1.5).
Table 3 Number of patients complaining of adverse effects and
acceptance to the study drugs
Combined phase Morphine-alone phase
Nausea* 1 8
Vomiting* 0 7
Dry mouth 3 2
Hallucination 0 0
Somnolence 7 11
Pruritus 1 1
Constipation 4 5
Sensation of empty head 1 0
Anorexia 14 13
Dyspnoea 0 0
Acceptance to the study drugs 22 21
Patient satisfaction 22 18
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drugs were not different among patients in the present
study (Table 3). Nevertheless, group sizes in the range of 30–60
would be more appropriate for accuracy of side effects (Moore
et al, 1998).
In conclusion, the rescue morphine analgesic consumption was
38% higher in patients receiving morphine only, compared to
patients receiving both morphine and oxycodone, suggesting that
the combination of morphine/oxycodone (opioids with differential
preferential sites of action) can be a useful alternative to morphine
alone, resulting in a better analgesia profile and less emesis.
Unfortunately, the cost of CRO treatment in Brazil would be nearly
three times more expensive than morphine alone.
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